JP Morgan Cuts Travere Therapeutics Price Target to $86 From $90
JP Morgan lowered its Travere Therapeutics price target to $86 from $90 while keeping an Overweight rating, according to Dow Jones Newswires citing Benzinga.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
JP Morgan has reduced its price target on Travere Therapeutics shares to $86 from $90. The bank kept its Overweight rating, meaning it still sees the stock as a better-than-market holding. The information was reported by Dow Jones Newswires, citing Benzinga ratings data.
why it matters
Analyst target revisions like this usually reflect updated models rather than a shift in market sentiment, and they rarely move a stock on their own. A $4 cut with the rating unchanged suggests a modest adjustment in valuation rather than a change of view.
tags
instruments
sources
- Travere Therapeutics Price Target Cut to $86.00/Share From $90.00 by JP Morgan — Dow Jones Newswires, 7 November 2026 at 03:11 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗